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Abstract
Ubiquitination, the covalent attachment of ubiquitin to proteins, by E3 ligases of the HECT (homologous to E6AP C ter-
minus) family is critical in controlling diverse physiological pathways. Stringent control of HECT E3 ligase activity and 
substrate specificity is essential for cellular health, whereas deregulation of HECT E3s plays a prominent role in disease. 
The cell employs a wide variety of regulatory mechanisms to control HECT E3 activity and substrate specificity. Here, we 
summarize the current understanding of these regulatory mechanisms that control HECT E3 function. Substrate specificity 
is generally determined by interactions of adaptor proteins with domains in the N-terminal extensions of HECT E3 ligases. 
These N-terminal domains have also been found to interact with the HECT domain, resulting in the formation of inhibi-
tory conformations. In addition, catalytic activity of the HECT domain is commonly regulated at the level of E2 recruit-
ment and through HECT E3 oligomerization. The previously mentioned regulatory mechanisms can be controlled through 
protein–protein interactions, post-translational modifications, the binding of calcium ions, and more. Functional activity is 
determined not only by substrate recruitment and catalytic activity, but also by the type of ubiquitin polymers catalyzed to 
the substrate. While this is often determined by the specific HECT member, recent studies demonstrate that HECT E3s can 
be modulated to alter the type of ubiquitin polymers they catalyze. Insight into these diverse regulatory mechanisms that 
control HECT E3 activity may open up new avenues for therapeutic strategies aimed at inhibition or enhancement of HECT 
E3 function in disease-related pathways.
Keywords Ubiquitination · HECT E3 ligase · Substrate recruitment · Intramolecular interaction · Activity regulation · 
Oligomerization · Post-translational modification
Introduction
Ubiquitination is a post-translational modification that is 
important for regulating protein function and degradation. 
The ubiquitination cascade comprises the sequential actions 
of the ubiquitin-activating enzyme (E1), ubiquitin-conju-
gating enzymes (E2s), and ubiquitin ligases (E3s) (Fig. 1). 
Within the ubiquitin cascade, the E3 ligases primarily deter-
mine specificity regarding selection of target proteins and 
ubiquitination sites. E3s are often focal points of cellular 
regulation and this makes them attractive targets for thera-
peutic intervention [1–3].
E3 ligases are commonly grouped into three classes: 
really interesting new genes (RINGs), homologous to E6AP 
C terminus (HECTs), and RING-between-RINGs (RBRs). 
While the three classes of E3 ligases all catalyze covalent 
attachment of ubiquitin to usually a Lys residue in the target 
protein, they differ in structure and mechanisms (reviewed 
in [4]). A notable distinction in the mechanism between 
the classes is that RING E3s catalyze a direct transfer of 
ubiquitin from the E2 to the target protein, whereas transfer 
of ubiquitin by HECT E3s (and RBR ligases) involves and 
intermediate step where the ubiquitin is first transferred from 
the E2 to an active-site cysteine residue on the HECT E3 
ligase before it is conjugated to the target protein. Target 
proteins can be modified by a single ubiquitin moiety on 
one or multiple sites, giving rise to mono- and multi-mono-
ubiquitinated proteins, respectively. In addition, a wide vari-
ety of polyubiquitin chains can be formed on target proteins, 
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in which the ubiquitin moieties can be linked through either 
one of the seven internal Lys residues (Lys6, Lys11, Lys27, 
Lys29, Lys33, Lys48, or Lys63) in ubiquitin or through its 
N-terminal amino group. The consequences for the modified 
target protein are determined by the type of (poly)ubiqui-
tin modification it received. Ubiquitination can result in the 
change of function, localization or activity of the modified 
protein, or control its degradation via the 26S proteasome 
(reviewed in [5]).
The identification of the E6AP protein transcribed from 
the ubiquitin-protein ligase E3A (UBE3A) gene led to the 
discovery of the HECT-type E3 ligase family [6–8]. HECT 
E3s are directly implicated in cancer, hypertension, neurode-
generative disorders, and other diseases, such as Angelman 
syndrome which is caused by the loss of maternally inher-
ited UBE3A [9, 10]. E6AP was discovered through its inter-
action with the human papillomavirus protein (HPV) E6, 
which hijacks the E3 ligase to ubiquitinate the p53 tumor 
suppressor as well as several other cellular proteins resulting 
in their degradation [11, 12]. In a non-infected cell p53 is 
not a target of E6AP, but the E6 protein alters the substrate 
specificity of the E3 ligase to target and ubiquitinate p53 
[7]. The interaction between the E6 protein and E6AP is one 
example of how a HECT E3 ligase is activated and altered 
to ubiquitinate a specific substrate through binding of an 
adaptor protein.
The interaction with adaptor proteins, such as the inter-
action of E6 with E6AP, can not only change the substrate 
Fig. 1  The ubiquitination cascade. The initial step involves the ATP-
dependent transfer of ubiquitin to an active-site cysteine residue on 
the E1 ubiquitin-activating enzyme. In the next step, the ubiquitin 
is transferred from the E1 to the E2 ubiquitin-conjugating enzyme. 
Once the E2 is charged with ubiquitin, it can associate with the E3 to 
prepare the ubiquitin transfer to the target protein. A RING-E3 will 
mediate a direct transfer of ubiquitin from the E2 to the target protein. 
The substrate ubiquitination by HECT E3s (and RBR ligases, not 
shown) involves an additional step where the ubiquitin is first chemi-
cally bound to an active-site cysteine of the HECT domain before it 
is attached to the target protein. Target proteins can be modified by 
mono-, multi-mono-, or polyubiquitin. As ubiquitin has seven internal 
lysine residues and an N-terminal amino group, all of which can be 
ubiquitinated, a wide variety of polyubiquitin chains can be formed 
(not shown). Depending on the type of (poly)ubiquitin modification, 
either the function/localization of the target protein is changed (“reg-
ulation”) or the target protein is sent for degradation by the 26S pro-
teasome (“degradation”)
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specificity of HECT E3s but also alter the structure of 
the ubiquitin polymers they conjugate to the substrates. 
Post-translational modifications (PTMs) are also preva-
lent in the alteration of HECT E3 ligase functionality such 
as phosphorylation and the attachment of ubiquitin-like 
modifiers (UBLs) [13–15]. Various mechanisms other than 
PTMs and interactions with adaptor proteins also regulate 
HECT E3 ligases such as intramolecular interactions, oli-
gomerization, and recruitment of the E2 (Fig. 2).
This review aims to give a comprehensive overview of 
the different mechanisms through which HECT E3 ligase 
activities and substrate specificities are regulated. The 
structural aspects of these regulatory mechanisms have 
been very recently surveyed [16], while the pathophysi-
ological aspects of HECT E3 ligases have been addressed 
by Scheffner and Kumar [17]. In addition to providing a 
clearer perspective of the regulation of HECT E3 ligases, 
this overview could show us which aspects of research on 
HECT E3s have made good progress and which areas of 
research have lagged behind. Together, these insights may 
lead to suggestions for future research and pave the way for 
new therapeutic strategies for many diseases.
HECT E3 ligases
HECT E3 ligases can be distinguished from other classes 
of ubiquitin E3 ligases in that they have an active-site 
cysteine that forms an intermediate thioester bond with 
ubiquitin before the ubiquitin is linked to its substrate 
[8, 18]. RING E3s do not have this catalytic activity, but 
rather act as allosteric activators of E2s that mediate the 
transfer of ubiquitin from E2 to substrate directly [19]. 
This direct transfer of ubiquitin from the E2 means that 
the linkage type of the ubiquitin chains catalyzed by RING 
E3s is generally determined by the specific E2 conjugat-
ing enzyme [20]. In contrast, HECT E3 ligases form an 
E3 ~ Ub intermediate prior to the transfer of ubiquitin to 
the substrate, allowing them to override any linkage-type 
preferences that an E2 conjugating enzyme may have [21]. 
Consistent with this, some HECT E3s appear to have a 
general preference for catalyzing chains of specific linkage 
types even when they cooperate with different E2s: E6AP 
predominantly assembles Lys48-linked chains [21–23]; 
Rsp5 and NEDD4.1 assemble preferentially Lys63-linked 
chains [21–23]; UBE3C promotes formation of Lys29- 
and Lys48-linked chains [22]; and recently it was shown 
that WWP1 assembles ubiquitin chains containing Lys63, 
Lys48, and Lys11 linkages [24]. For most other HECT 
E3s their linkage-type preferences, if any, remain to be 
discovered. Along with ubiquitin, HECT E3s are found in 
all eukaryotic organisms. HECT domain-like E3 proteins 
have also been found in pathogenic bacteria [25]. These 
bacteria presumably exploit the ubiquitin system of their 
host cells by injecting them with the respective HECT 
domain-like E3s [26]. Another characteristic of some 
HECT E3 ligases is that they are capable of catalyzing 
UBL proteins to their substrates such as NEDD8 (neural 
precursor cell expressed developmentally down-regulated 
protein 8) [14] and ISG15 (ubiquitin-like modifier IFN-
stimulated gene 15) [27–29].
The HECT domain
The HECT domain is an approximately 40 kDa domain 
positioned at the C-terminal of the E3 ligases that consists 
of two flexibly tethered lobes (the N- and C-lobes). Across 
the HECT family, there is a 16–92% amino-acid identity 
for the domain [30]. The larger N-lobe (approximately 
250 amino acids) contains the docking surface for the E2 
[31]. The short flexible hinge connects the N-lobe to the 
shorter C-lobe, which contains the active-site cysteine. 
Non-covalent interactions between the E2 and the N- 
and C-lobes influence the conformation of the HECT-E2 
Fig. 2  Modes of regulating HECT E3 ligase function. Mechanisms 
that can regulate or modulate HECT E3 ligase function are: (1) 
recruitment of substrate and activity modulation by adaptor proteins/
co-activators, (2) recruitment of E2, (3) intramolecular interaction 
between an N-terminal domain and the HECT domain, (4) intermo-
lecular interaction/oligomerization, (5) post-translational modifica-
tion, and (6) ubiquitin binding to the “exosite” on the HECT domain. 
For details see text
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complex depending on the ubiquitin-loading status of the 
E2. A crystal structure of the E6AP HECT domain with 
an unloaded E2 shows a large distance between the E2 
and HECT domain cysteines [31]. A subsequent struc-
ture of the NEDD4.2 HECT with an ubiquitin-loaded E2 
revealed a large change in E2–E3 topology, bringing the 
cysteines of both proteins in close proximity [32] (Fig. 3). 
These structural rearrangements, which are required for 
catalysis, are dependent on the flexibility of the linker that 
connects the N- and C-lobes of the HECT domain [33]. 
Properties of the E2 docking surface on the HECT domain 
in combination with the E2-conjugating enzyme involved 
may determine the efficiency at which ubiquitin chains are 
elongated. This is presumed because polyubiquitin chain 
synthesis requires multiple E2–E3 binding events due to 
an overlapping binding domain on the E2 for E1 and E3 
[34].
HECT E3 families
Among the various HECT E3 ligases, a large variety of con-
figurations are observed in the region located N-terminal to 
the HECT domain. The human HECT E3 family consists of 
28 members of which 15 members can be categorized into 
two subfamilies based on commonalities in the N-terminal 
domains (Fig. 4). The human NEDD4 subfamily, charac-
terized by the presence of WW and C2 domains, has nine 
members and is the most prominent and well studied of 
the two families. The other family is the HERC E3 ligases 
that consist of six members and have in common that they 
contain one or more regulator of chromatin condensation 
1(RCC)-like domains (RLD). Yeast has five HECT E3 
ligases: Rsp5, Ufd4, Hul4, Hul5, and Tom1. Rsp5 is a 
member of the NEDD4 family, whereas the other four yeast 
HECT E3s do not belong to any family. Rsp5 is also the only 
HECT E3 that is essential for the viability of the yeast. Each 
of the members of the “other” human HECT E3s lack WW 
or RLD domains and have a distinct variety of N-terminal 
domains (Fig. 4).
NEDD4 subfamily
The NEDD4 subfamily is the largest and best character-
ized family of the HECT E3s. The N-terminal C2 domain 
is defined as a  Ca2+ and phospholipid binder [35]. Consist-
ent with observed NEDD4 ligase functions, C2 domains 
are known for targeting their proteins to phospholipid 
membranes [36]. The C2 domain can also bind to substrate 
proteins to target them for ubiquitination [37, 38]. In some 
NEDD4 E3s, the C2 domain is involved in regulating the 
activity of the HECT domain, as it is capable of binding to 
the HECT domain, thereby folding the E3 into an auto-inhib-
itory conformation [39]. The NEDD4 subfamily can contain 
between two and four WW domains. The WW domains are 
responsible for the recognition of substrates [40] and have 
also been found to form intramolecular interactions with the 
HECT domain of the E3s [41].
HERC subfamily
The HERC subfamily is characterized by having one or more 
RCC-like domains (RLDs), an effector protein domain that 
was first identified in RCC1 [42]. In humans, the HERC 
Fig. 3  Structural rearrange-
ments in the catalytic HECT 
domain. Illustration of alternate 
HECT domain C-lobe positions 
as seen in the crystal struc-
tures of UbcH7 (not shown 
for clarity)-E6APHECT (green) 
(PDB ID: 1C4Z) and UbcH5b 
(salmon) ~ Ubiquitin (not shown 
for clarity)-NEDD4.2HECT 
(cyan)(PBD ID: 3JW0). The 
flexible linker that allows for 
rearrangements of the N- and 
C-lobes with respect to each 
other is indicated. Catalytic 
cysteine residues are displayed 
as yellow balls. For details see 
text
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subfamily comprises six members, which can further be 
organized into two large and four small HERCs (Fig. 4). 
HERC1 and HERC2 are large HERCs that contain two and 
three RLDs, respectively. The small HERCs contain only 
one RLD. RLDs have dual functions as one side of the 
domain acts as a guanine nucleotide exchange factor (GEF) 
for the small GTPase Ran and the opposite side interacts 
with chromatin through histones H2A and H2B [43, 44]. 
Through their interactions with histones, HERC E3 ligases 
participate in various processes at the chromatin and in the 
nucleus (reviewed in [45]).
“Other” HECT E3s
E6AP, the founding member of the family of HECT E3 
ligases, is profoundly impactful on the regulation of the 
cell and has been extensively studied. Located at the N 
terminus (residues 24–87), E6AP harbors a zinc-binding 
fold called the AZUL (amino-terminal Zn-finger of Ube3a 
ligase) domain of which mutations have been associated 
with Angelman syndrome [46]. Another notable feature 
of the E6AP protein is an LxxLL motif (where x denotes 
any residue) located in the center of the protein (residues 
379–395), which is the binding site of E6 [47] (for details, 
see “adaptor proteins and co-activators”). Although not stud-
ied as thoroughly as E6AP, the members HUWE1, UBR5, 
TRIP12, and HACE1 have also been subject to a signifi-
cant amount of research (reviewed in [17]). HUWE1 is a 
giant 4374 amino-acid residue protein that contains a WWE 
domain, a BH3 domain, an UBA domain, and Armadillo 
repeats (ARM). HUWE1 naturally targets the p53 tumor 
suppressor for degradation, in contrast to E6AP which only 
targets p53 once it is hijacked by the viral E6 protein [48]. 
TRIP12 has also been implicated in the regulation of p53; 
however, this regulation is indirect through the targeting of 
p14ARF, a key regulator of p53 [49]. Another commonality 
between TRIP12 and HUWE1 is the presence of a WWE 
domain and Armadillo repeats. Other domains shared among 
this family of HECT E3s are the UBA domain (UBR5 and 
HUWE1), Ankyrin repeats (HACE1 and HECTD1), and IQ 
motifs (UBE3B and UBE3C).
Substrate recruitment and catalytic activity 
regulation
Adaptor proteins and co‑activators
A prominent mechanism that regulates the substrate-specific 
conjugation of ubiquitin is the recruitment of HECT E3s 
to their substrates by adaptor proteins. Assuming that the 
HECT E3 is in an active state, adaptors proteins can recruit 
the E3 to its ubiquitination substrate, thereby contributing to 
the ubiquitination activity and substrate specificity. HECT 
E3 adaptors associate with the E3 ligases by binding to 
domains in the N-terminal regions or to regions within the 
HECT domain.
A classic example of a HECT adaptor is the viral protein 
E6, which was the protein that led to the discovery of the 
HECT E3 ligases [6–8]. E6 is one of the two viral proteins 
expressed in HPV (human papilloma virus)-positive cervi-
cal carcinomas, the other being E7, which also utilizes the 
cell proteasomal system to inactivate its targets [50]. The 
two viral proteins each have an enormous impact on host 
gene expression patterns, and their oncogenic role is mainly 
attributed to their inactivation of tumor suppressors p53 and 
retinoblastoma (pRb) [7, 11, 51, 52]. The E7 oncoprotein is 
thought to target the pRb tumor suppressor using the cullin 2 
ubiquitin ligase complex; however, this mechanism remains 
controversial [53, 54]. With regards to the E6 oncoprotein, it 
is clear that it hijacks E6AP by binding to the LxxLL motif 
located in the N-terminal domain of E6AP and utilizes the 
activity of its HECT domain to ubiquitinate p53, thereby 
marking it for degradation by the 26S proteasome [47] 
(Fig. 5a). Recent structural analysis has revealed that the 
binding pocket for the LxxLL motif on E6 is formed by two 
zinc domains and a linker helix [55]. Other than redirecting 
E6AP substrate specificity to ubiquitinate p53, the E6/E6AP 
complex also ubiquitinates other cellular proteins, the degra-
dation of which contributes to E6-induced cellular immor-
talization or transformation [56]. These include the TERT 
(telomerase reverse transcriptase) gene repressor NFX1-91, 
resulting in increased telomerase activity [57, 58], E6TP1 
(E6 targeted protein 1) [59, 60], MCM7(mini chromosome 
maintenance protein 7) [61], and BAK (Bcl-2 homologous 
antagonist killer) [62]. Consistent with this, knockout studies 
of E6 and E6AP have shown that E6 relies virtually exclu-
sively on E6AP to alter the cellular gene expression [63].
The alterations that E6 binding creates in the substrate 
specificity of E6AP cannot always simply be explained by 
the binding of E6 to substrates. Studies have shown that 
p53 does not bind E6AP or the E6 adaptor in isolation from 
each other [64], whereas other studies showed only weak 
and insignificant E6–p53 interactions [65, 66]. Consistent 
with this, a recent analysis of the crystal structure of the 
E6/E6AP/p53 ternary complex showed that the p53 binding 
cleft on E6 is formed upon binding of the LxxLL peptide 
[67]. Other substrates recruited to the E6/E6AP complex 
by E6 show that the viral protein does function in a manner 
expected from an adaptor protein. For example, the E6 pro-
teins of ‘high-risk’ HPV have a C-terminal PDZ (named for 
the proteins PSD95, DLG, and ZO1) domain-binding motif 
(PBM) through which they bind PDZ-domain-containing 
substrates irrespective of whether the E6 is in complex with 
E6AP [68]. Nineteen PDZ-domain-containing proteins have 
been confirmed as binding partners of E6, of which several 
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are known as tumor suppressors [69, 70]. Experiments 
with cell and mouse models show that the PBM is impor-
tant for carcinogenesis [71–74] and that this is reliant upon 
proteolytic targeting of PDZ-domain-containing substrates 
by the E6/E6AP complex [75–77]. This is consistent with 
the observation that all cancer-causing HPV types contain 
a PBM, whereas low-risk HPV types often do not contain a 
PBM (reviewed in [70]).
The binding of E6 to E6AP does not only affect its 
substrate recognition, but also the catalytic activity of its 
HECT domain is increased. Consequently, its regular sub-
strate proteins are also increasingly ubiquitinated by the E6/
E6AP complex [78]. Notably, a similar allosteric interaction, 
which enhances E6AP activity, has been seen with HERC2. 
HERC2, another HECT E3, binds to E6AP in a region on 
the N terminus (residues 150–200) and thereby increases 
the catalytic activity of E6AP [79]. Together these studies 
show that E6 is a versatile adaptor that recruits substrates to 
the E6AP complex and additionally increases the catalytic 
activity of the HECT domain through allosteric interactions.
It should not come as a surprise that viruses utilize adap-
tors to control HECT E3 ligases, as the cell also commonly 
uses them to regulate HECT E3s. Some of the most exten-
sively studied cellular adaptors are those that interact with 
the WW domains of the NEDD4 subfamily. Adaptors of 
NEDD4 typically contain PY motifs (PPxY or LPxY, x is 
any residue) that interact specifically with WW domains [80, 
81]. One informative example of a target that is recruited 
to NEDD4 E3 ligases through interaction with PY motif-
containing adaptors is PTEN (phosphatase and tensin 
homolog). PTEN is a plasma membrane lipid phosphatase 
that acts as an antagonist of the phosphatidylinositol-3-ki-
nase (PI3K) signaling pathway by dephosphorylating the 
second messenger phosphatidylinositol 3,4,5-trisphosphate 
 (PIP3) to phosphatidylinositol 4,5-bisphosphate  (PIP2) [82]. 
Through its role in phosphatidylinositol homeostasis, PTEN 
is recognized as a pivotal tumor suppressor and regulator 
of cellular processes including proliferation, survival, and 
migration [83]. Several PY motif adaptors have been found 
to mediate PTEN ubiquitination including NDFIP1 (Nedd4 
family-interacting protein 1) and NDFIP2 and more recently 
NUMB. The NDFIP adaptors can recruit various NEDD4 
E3s to target PTEN either for degradation or nuclear trans-
location [84–86] (Fig. 5b). In response to ischemia, NDFIP1 
recruits NEDD4.1 or NEDD4.2 to mono-ubiquitinate PTEN, 
which leads to translocation of PTEN to the nucleus [84], 
where it controls processes not related to  PIP3 hydrolysis 
such as chromosome integrity and cell cycle progression 
[83]. By contrast, NDFIP-mediated recruitment of PTEN to 
the HECT E3 WWP2 results in PTEN poly-ubiquitination 
and its subsequent degradation [85]. These observations 
suggest that the HECT E3 that is recruited by the adaptor 
determines the outcome for the substrate. WWP2 likely 
ubiquitinates PTEN with Lys48 and/or Lys11-linked chains 
that are commonly associated with proteasomal degradation, 
whereas NEDD4.1 has been shown to mono-ubiquitinate 
PTEN [86], a modification often associated with non-prote-
olytic functions. Intriguingly, recruitment of NEDD4.1 by 
a different adaptor, NUMB, results in PTEN poly-ubiqui-
tination and degradation [87], suggesting that the adaptor 
may also influence the type of ubiquitin chain catalyzed 
by the HECT E3. Another NEDD4 member regulated by 
NDFIP1 is ITCH, an E3 ligase that targets the transcription 
factor JunB for degradation in a way reminiscent to that of 
the recruitment of WWP2 to the substrate PTEN. Indeed in 
the absence of NDFIP1, ITCH cannot bind JunB to ubiqui-
tinate it, resulting in the accumulation of JunB. Consistent 
with this, the absence of NDFIP1 has been shown to cause 
inflammation in mice as a result of JunB accumulation [88].
Interactions of PY-containing adaptors with the WW 
domains of HECT E3s are also seen for viral proteins 
(Fig. 5c). The viral protein VP40, which is found in the filo-
viruses Ebola (eVP40) and Marburg (mVP40), contains a 
proline-rich PPxY motif that it utilizes to hijack NEDD4.1 
through binding of its third WW domain [89, 90]. The 
release of viral particles is dependent on the binding of VP40 
to NEDD4.1, thereby hijacking its ubiquitination activity to 
mediate virus budding [91]. A recent study also showed that 
the VP40 proteins hijack ITCH to regulate the budding pro-
cess [92]. Given the HPV viral protein E6 hijacking E6AP 
to suppress p53 and VP40 hijacking NEDD4 family E3s 
to mediate virus budding, it is ostensible that HECT E3s 
are desirable targets which viruses can use to control their 
host cells. Hence, inhibiting these HECT E3–viral protein 
Fig. 4  Human HECT E3 protein domain architecture. Overview of 
the domain organization of human HECT E3 ligases. Protein domains 
were predicted by the InterPro server [156]. HECT E3 ligases are 
characterized by the presence of a conserved HECT (homologous 
to E6AP C-terminus) domain that is located at the C-terminus of 
the proteins. The human HECT E3 ligase family is grouped into two 
subfamilies and 13 “other” HECT E3 ligases based on their domain 
architecture N-terminal to the HECT domain. The NEDD4 subfamily 
comprises nine members each having an N-terminal C2 domain and 
between two and four WW domains. The HERC subfamily has six 
members that each contains between one and three RLDs (RCC-like 
domains) while the two large family members, HERC1 and HERC2, 
additionally contain various other domains. The “other” HECT E3 
ligases contain various domains as shown. Domain abbreviations 
used are as follows: C2 C2 domain  (Ca2+-binding domain), WW WW 
domain, RLD RCC-like domain, SPRY B30.2/SPRY domain, WD40 
W-D repeat domain, Cytb5 cytochrome b5-like heme/steroid-binding 
domain, DOC APC10/DOC domain, MIB MIB-HERC2 domain, 
AZUL amino-terminal Zn-binding domain of UBE3A ligase, ARM 
Armadillo repeat-containing domain, UBA ubiquitin-associated 
domain, WWE WWE domain, BH3 Bcl-2 homology 3 domain, ANK 
Ankyrin repeat-containing domain, ZnF Zinc finger domain, PABC 
polyadenylate-binding protein C-terminal domain, IQ IQ motif/
EF-hand binding site, PHD PHD-type zinc finger, Filamin filamin/
ABP280 repeat-like domain
◂
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interactions, for example, with small molecules can be of 
therapeutic relevance. Indeed various compounds have 
been found that inhibit the interaction between the Ebola 
and Marburg virus VP40 proteins and NEDD4 HECT E3s 
[93]. Although these compounds may inhibit interactions 
of NEDD4 with any PPxY motif-containing protein, they 
are still attractive potential antiviral agents. Screens for 
small molecule inhibitors have also been successfully done 
to find compounds that inhibit the interaction between E6 
and E6AP [94]. Several of these inhibitory compounds were 
shown to block p53 degradation in HPV-infected cells. Fur-
ther study of these compounds may lead to the development 
of beneficial therapeutics.
Regulation by recruitment of E2‑conjugating 
enzymes
HECT ubiquitination activity is also regulated at the level 
of recruiting E2-conjugating proteins. SMAD7 functions as 
an adaptor for SMURF1 and SMURF2 by recruiting these 
HECT E3s to their substrate the TGF-β receptor [95]. Simi-
lar to the mechanism of NDFIP1- and NDFIP2-mediated 
recruitment described previously, SMAD7 has PY motifs 
that interact with the WW domains of the SMURF E3s. In 
addition to its function as an adaptor, SMAD7 also has a 
function to activate the HECT domain. SMAD7 recruits 
UbcH7, the E2-conjugating enzyme of SMURF2, thereby 
enhancing the ubiquitin ligase activity of the E3 [96]. To 
facilitate E2–E3 interaction, SMAD7 binds the HECT 
domain of SMURF2 and binds UbcH7 with its N-terminal 
domain (Fig. 6a). Analysis of the E2-binding domain of 
SMURF2 suggested that SMURF2 has an inherent low affin-
ity for its E2-conjugating enzyme. This low E2–E3 binding 
affinity suggests that the E3 enzyme is dependent on other 
proteins for optimal interaction with its E2-conjugating 
enzyme and thus its ubiquitination activity.
In addition to the recruitment of E2s by adaptors, inhibi-
tors that prevent the HECT E3s from interacting with 
Fig. 5  Modulation of HECT E3 ligase function by adaptor proteins 
and co-activators. a Binding of the HPV E6 protein to a conserved 
sequence (LxxLL motif, not shown) in the N-terminal domain of 
E6AP allows the E6/E6AP complex to recruit the tumor suppressor 
protein p53. E6AP-dependent ubiquitination of p53 targets the protein 
for proteasomal degradation, thereby promoting HPV-induced cer-
vical carcinogenesis. Not shown are the other targets inactivated by 
the E6/E6AP complex whose degradation may contribute to carcino-
genesis. b NDFIP1, a PY motif-containing adaptor, recruits HECT 
E3 ligases of the NEDD4 subfamily to their substrate. In response 
to ischemia, NDFIP1 recruits NEDD4 to mono-ubiquitinate PTEN, 
resulting in translocation of PTEN into the nucleus. Recruitment of 
WWP2 HECT E3 ligase by the NDFIP1 adaptor results in poly-ubiq-
uitination of PTEN, thereby targeting PTEN for proteasomal degrada-
tion. c The viral VP40 protein hijacks NEDD4.1 thereby promoting 
ubiquitination of viral proteins and stimulating the viral budding pro-
cess
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E2-conjugating enzymes can also regulate HECT activ-
ity. The interaction of NEDD4.1 with its E2-conjugating 
enzyme is negatively regulated by interactions with ISG15, 
an ubiquitin-like protein. The resulting decrease in NEDD4 
E3 ligase activity causes a reduced ubiquitination of the 
Ebola virus VP40 (discussed in the previous section), 
thereby blocking viral budding [97, 98] (Fig. 6b). ISG15 is 
an interferon-stimulated gene that can be present in the cell 
in free form or covalently bound to a substrate as a result 
of an enzymatic process called ISGylation [99]. ISGyla-
tion of NEDD4.1 is not necessary to obtain the inhibitory 
effect on NEDD4.1; non-covalent interactions of ISG15 with 
NEDD4.1 are sufficient to prevent the E2–E3 interaction.
Inter‑ and intramolecular interactions of HECT E3 
ligases
HECT E3 ligases are often regulated by intramolecular (i.e., 
within the same molecule) or intermolecular (i.e., with other 
identical proteins) interactions. Through these intra- and 
intermolecular mechanisms, the HECT E3s can control the 
activity of their own catalytic domain. Often these mecha-
nisms determine the default state of the HECT protein and, 
thus, regulatory proteins that change these inter- and intra-
molecular interactions can control the activity of the HECT 
E3.
Interactions of N‑terminal domains with the HECT domain
Some HECT E3s can arrange themselves into inactive con-
formations by interactions of the N-terminal region with the 
HECT domain. Several of the WW and C2 domains of the 
NEDD4 E3s can interact with their corresponding HECT 
domains, thereby blocking access to the catalytic site. Due to 
these conformations, it is common for NEDD4 E3 ligases to 
have a default state of auto-inhibition. Although the domain 
architecture of the NEDD4 family is similar, the mecha-
nisms of auto-inhibition vary [39, 100, 101]. Two exem-
plary mechanisms of auto-inhibition can be found in ITCH 
and SMURF2 (Fig. 7). The auto-inhibited state of ITCH is 
acquired through the binding of its WW domain region to its 
HECT domain (Fig. 7c) [41]. Recent structural analysis has 
revealed further details of the auto-inhibitory conformation 
of ITCH: the interface of the auto-inhibited ITCH involves 
the second WW domain (WW2) and a linker region connect-
ing WW2 and WW3 [102]. The WW3 domain may still be 
relevant for auto-inhibition as previous research established 
that mutations in either WW2 or WW3 resulted in activation 
of ITCH [101]. The importance of the WW2–WW3 linker 
region in regulating E3 ligase activity was recently con-
firmed for WWP2, a HECT closely related to ITCH [103]. 
Indeed, Chen et al. establish that a linker region connecting 
the WW2 and WW3 domains is necessary to lock the E3 in 
its auto-inhibitory conformation. The SMURF2 inhibitory 
state is acquired similarly, but instead of the WW domain 
region it is its C2 domain that binds to the HECT domain 
(Fig. 7b) [39]. Similar to SMURF2, interactions between the 
C2 and HECT domains also inhibit SMURF1 (Fig. 7a). In 
contrast, SMURF1 inhibitory interactions are not intramo-
lecular. SMURF1 is not able to fold into an intramolecular 
auto-inhibitory state likely due to the shorter nature of the 
protein. Instead, the C2-HECT domain auto-inhibitory inter-
actions of SMURF1 proteins are facilitated by the formation 
of homodimers [104].
The regulatory mechanisms that the cell uses to control 
HECT E3s often revolve around relieving previously dis-
cussed auto-inhibitory interactions. Intuitively, a wide vari-
ety of mechanisms can be envisioned that relieve these auto-
inhibitory and homo-oligomeric interactions. The previously 
mentioned examples of ITCH, SMURF1, and SMURF2 
Fig. 6  Regulation of E3-E2 interactions. a Binding of SMAD7 to 
SMURF2, through interaction of its PY motifs with one of the WW 
domains in SMURF2, not only relieves the auto-inhibitory conforma-
tion of the HECT E3 (see Fig. 7b) but also stimulates E2 binding: the 
amino-terminal domain (NTD) of SMAD7 contacts both the SMURF 
HECT and the E2, thereby enhancing E2 binding and ubiquitin ligase 
activity. b Non-covalent binding of interferon-stimulated gene 15 
(ISG15) to NEDD4.1 blocks interaction of the HECT E3 with its 
E2-conjugating enzyme, resulting in reduced E3 ligase activity
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inhibitions also provide good examples of the various 
mechanisms that relieve inhibition (Fig. 7). SMURF2 auto-
inhibition is relieved by the binding of its substrate SMAD7 
to the WW domain adjacent to the HECT domain (Fig. 7b) 
[105]. Disruption of the SMURF1 homodimer is achieved 
by allosteric interactions of several adaptor proteins includ-
ing CKIP (casein kinase-interacting protein), which binds 
to the WW domain [106]; CDH1 (Cadherin 1), which binds 
to the C2 domain [104]; or CCM2 (cerebral cavernous mal-
formations 2), which binds to the HECT domain (Fig. 7a) 
[107]. Recent evidence suggests that CKIP and CDH1 have 
different roles in SMURF1 activation [108]. While CDH1 
is required for disruption of the auto-inhibited SMURF1 
homodimer, CKIP1 promotes binding and ubiquitination 
of SMURF1 substrates. The auto-inhibitory conformation 
of ITCH is relieved by phosphorylation (Fig. 7c). In this 
instance, ITCH is phosphorylated at residues S199, S232, 
and T222, all of which are located in a proline-rich region 
(PRR) between the C2 and WW domains [101]. PY motif-
containing interactors such as NDFIP1 and NDFIP2 can 
also release auto-inhibition through their interactions with 
WW domains [102]. To release auto-inhibitory conforma-
tions involving the WW-linker-binding interface such as in 
ITCH, the PY motif-containing co-activators are likely to 
Fig. 7  Modes of relief of auto-inhibitory interactions of the NEDD4 
subfamily. Various mechanisms are known to relieve auto-inhibitory 
interactions between HECT and C2/WW domains. SMURF1 forms 
an auto-inhibited homodimer through intermolecular interaction of 
the C2 domain of one monomer with the HECT domain of the other 
(a), while in all other known NEDD4 subfamily members the auto-
inhibitory conformation is mediated by intramolecular interactions 
involving C2 or WW domains and the HECT domain (b–e). a Allos-
teric interactions of various adaptor proteins with SMURF1 disrupt 
the SMURF1 auto-inhibited homodimer and promote substrate bind-
ing. CDH1 (Cadherin 1) and CKIP1 (Casein kinase-2 interacting 
protein 1) may work sequentially: interaction of CDH1 with the C2 
domain disrupts the SMURF1 homodimer, subsequent binding of 
CKIP1 to the linker region between the WW domains promotes bind-
ing and ubiquitination of SMURF1 substrates. b Binding of SMAD7 
to WW domains of SMURF2 relieves auto-inhibition and enhances 
E2 binding, thus stimulating E3 ligase activity (see also Fig.  6a). 
Serine/threonine phosphorylation of ITCH in a proline-rich region 
between the C2 and WW domains (c) or tyrosine phosphorylation of 
the NEDD4.1 C2 domain (d) relieves auto-inhibition. e The increase 
in  Ca2+ concentration in the cell disfavors the NEDD4.2 C2-HECT 
domain contacts, thereby relieving the auto-inhibitory conformation. 
In the presence of  Ca2+, the C2 domain can bind  PIP2 (phosphati-
dylinositol 4,5-bisphosphate) head groups in the membrane or  IP3 
(inositol 1,4,4-triphosphate) molecules in the cytoplasm, which may 
in turn determine the intracellular localization of the HECT E3 ligase. 
L linker region connecting the WW2 and WW3 domains. For details, 
see text
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rely on multiple PY–WW interactions able to disrupt the 
auto-inhibitory WW-linker to HECT binding. This linker 
region may also be directly targeted to relieve auto-inhibi-
tion. The WW2–WW3 linker contains tyrosine phosphoryla-
tion sites, and experiments mimicking phosphorylation of 
these sites in WWP2 showed increased activity of the HECT 
[102]. The linker regions connecting the various N-terminal 
domains of HECT E3 ligases may have a more impactful 
role on HECT regulation than previously anticipated. Chen 
et al. [103] discuss a linker region C-terminal of the WW1 
domain in NEDD4.1 that has an α-helical structure simi-
lar to the WW2–WW3 linker in WWP2. Indeed deletion of 
this linker region in NEDD4.1 resulted in increased auto-
ubiquitination activity. In addition, tyrosine phosphorylation 
has been shown to relieve the auto-inhibitory interactions of 
NEDD4.1 (Fig. 7d). NEDD4.1 is phosphorylated at a tyros-
ine residue in the C2 and in the HECT domain by c-Src 
kinase [13].
NEDD4.2 is regulated by its C2 domain through another 
distinct mechanism (Fig. 7e). The auto-inhibited form of 
NEDD4.2 is stabilized by the interaction of its C2 domain 
with its HECT domain. Increased  Ca2+ concentration in the 
cell leads to the activation of NEDD4.2 by disrupting this 
auto-inhibitory conformation [109]. The HECT-binding 
site on the C2 domain is shared with the  Ca2+ binding site, 
suggesting that the  Ca2+ interactions cause repulsion of the 
HECT domain. In addition to the activation of NEDD4.2, 
these interactions may also be involved in the localization 
of the HECT E3 ligase. NEDD4.2 can be relocated through 
interactions of its C2 domain with the head group of phos-
phatidylinositol 4,5-bisphosphate  (PIP2) and its second 
messenger inositol 1,4,5-trisphosphate  (IP3), which is the 
soluble version of the  PIP2 head group. The interactions of 
 PIP2 and  IP3 are facilitated by  Ca2+ ions that form a bridge 
to the C2 domain.  PIP2 prefers localization at the cell mem-
brane, whereas  IP3 prefers to diffuse throughout the cyto-
plasm. The  PIP2/IP3 ratio can determine the distribution of 
NEDD4.2 as localization of the E3 depends on which of the 
two molecules it associates with [109]. These results may 
suggest phospholipase C (PLC) as an important upstream 
regulator of NEDD4.2 as PLC triggers the increase of  Ca2+ 
in the cytoplasm and controls the ratio of  PIP2/IP3 through 
the hydrolysis of  PIP2. Since all NEDD4 ligases contain a 
C2 domain, the discussed regulation through  Ca2+ may be 
more common among this HECT E3 family.
Ubiquitin‑binding domain controlled oligomerization
Formation of intermolecular interactions between identi-
cal HECT E3 ligases has also been studied in the NEDD4 
yeast ortholog Rsp5. Similar to SMURF1, Rsp5 does not 
appear to be inhibited by intramolecular interactions [39], 
but rather through the formation of Rsp5 oligomers [110, 
111]. However, the inhibitory interactions of Rsp5 are sub-
stantially different from the previously discussed inhibitory 
interactions of NEDD4 ligases between the C2 and HECT 
domains. Rsp5 is proposed to utilize an oligomerization 
interface in its HECT domain to form inhibitory trimers. 
Interestingly, the experiments of Attali et al. suggest that 
the accessibility of this trimerization interface is con-
trolled by the ubiquitination of specific lysine residues in an 
α-helical segment N-terminal to the HECT domain, called 
the α1-helix [33]. The HECT ubiquitin-binding domain 
(HECT-UBD), also known as the ‘exosite’ [112, 113], has an 
important role in this regulatory mechanism as its pull on the 
ubiquitin conjugated α1-helix is suggested to lead to a con-
formational change that exposes the trimerization interface 
[110]. The resulting trimerization shuts down the catalytic 
activity of the HECT domain. Conservation analysis of the 
α1-helix domain suggested that this oligomerization mecha-
nism is also prevalent among human NEDD4 ligases. Exper-
iments using NEDD4.1 with a ubiquitin-fused α1-helix and 
a NEDD4.1K523,525R mutant that cannot be ubiquitinated at 
its α1-helix are consistent with this [110]. Ubiquitin-fused 
NEDD4.1 results in its oligomerization and diminished 
ubiquitination activity, whereas NEDD4.1K523,525R did not 
form oligomers and exhibited increased activity. Thus, ubiq-
uitination of the α1-helix may be an important regulatory 
mechanism to control the activity of various NEDD4 ligases. 
As NEDD4.1 auto-ubiquitinates the α1-helix, a deubiquit-
inating enzyme may control the activity of the E3. It may 
be that the α1-helix ubiquitin-mediated oligomerization 
is as common as the C2-HECT domain oligomerization, 
where the former is controlled by the ubiquitin status of the 
α1-helix and the latter by phosphorylation or  Ca2 binding.
Activating E6AP–E6AP interactions
Oligomerization may also play a role in the activa-
tion of HECT E3s rather than their inhibition. E6AP 
trimerization has been reported to promote its ubiqui-
tin ligase activity [114]. Early evidence for coopera-
tive E6AP–E6AP interactions were already suggested, 
because E6AP was only found to efficiently auto-ubiqui-
tinate in the presence of other E6AP enzymes, suggesting 
intermolecular transfer of ubiquitin [115]. In support of 
an oligomeric structure of E6AP, crystallographic analy-
sis of its HECT domain revealed a trimeric arrangement 
that is stabilized through N-lobe/N-lobe interactions 
[31]. However, the trimeric form of E6AP was initially 
dismissed as the HECT domain construct is monomeric 
in solution and a mutation in the trimerization interface 
(F727A) did not affect the ability of the enzyme to trans-
fer ubiquitin from E2 to its active site [31]. Rather than 
forming oligomeric complexes, the interactions between 
E6AP were proposed to be transient and the trimeric form 
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of the E6AP HECT domain in the crystal was attributed 
to a crystallization artifact. However, recent biochemical 
experiments showed that GST (glutathione S-transferase)-
fused E6AP has an increased poly-ubiquitin chain for-
mation in vitro compared to the un-fused E6AP. These 
observations suggested that GST–GST interactions [116] 
promote E6AP oligomerization resulting in increased 
activity, which prompted further research into the role 
of E6AP oligomerization [114]. Kinetic and biophysical 
experiments with the un-fused, full-length, E6AP pro-
vided stronger evidence for an activating role of E6AP 
oligomerization, as E6AP trimers were found to be more 
active than their monomeric counterparts. In support of 
this, mutation of a key residue in the trimerization inter-
face of E6AP, F727, which binds to a hydrophobic pocket 
of the adjacent subunit, substantially decreased the cata-
lytic activity of E6AP using polyubiquitin chain forma-
tion as a functional readout. The E6AP trimer harbors a 
second subunit interface important for the stabilization of 
the trimer [31, 114, 117]. The second interface is located 
further from the catalytic site. Interactions at this second 
interface were shown to be regulated by tyrosine phos-
phorylation [117], which is discussed more elaborately 
in the chapter of post-translational modifications. Muta-
tion of key residues at this second subunit interface also 
reduce the catalytic activity of E6AP [114], further sup-
porting the notion that the fully active form of E6AP is 
a trimer.
Remarkably, none of the other crystallized HECT 
domains forms a crystallographic trimer (reviewed in [16, 
118]), suggesting that trimerization is a unique feature of 
the E6AP HECT domain. However, the crystallized E6AP 
HECT construct lacks an α-helix segment N-terminal of 
the HECT domain (α-1 helix; previously discussed to 
regulate Rsp5 oligomerization) that is present in all other 
crystallized HECT domain constructs. In these structures 
the α-1 helix shields the hydrophobic pocket otherwise 
occupied by F727, suggesting that the presence of the α-1 
helix in these HECT domain constructs may prevent trim-
erization. In support of a role of the α-1 helix in regulating 
E6AP oligomerization, Ronchi et al. [114] showed that 
the addition of a peptide corresponding to the α-1 helix 
promoted the dissociation of the E6AP trimer and strongly 
reduced its E3 ligase activity in vitro. It is remarkable that 
trimerization of E6AP and Rsp5 seems to have opposing 
outcomes, namely activation of the former and inactivation 
of the latter. Although modeling has suggested that Rsp5 
(and possibly other NEDD4 family members) uses similar 
interfaces as E6AP to form trimers [110], further structural 
analysis is required to confirm this hypothesis. In addition, 
there is currently no structural information available on the 
full-length proteins. Therefore, it remains unclear what 
the contribution is of the regions N-terminal to the HECT 
domain as well as if/how intra- and intermolecular interac-
tions impact E3 ligase function in the proposed trimers.
HUWE1 oligomerization and auto‑inhibition
HUWE1 is a HECT E3 that can be down-regulated through 
a combination of oligomerization and auto-inhibitory inter-
actions [119]. HUWE1 forms an auto-inhibitory homodi-
mer where both inter- and intramolecular interactions are 
involved in the inhibition. In this case, a crystal structure 
of the C-terminal domain of HUWE1 revealed an asym-
metric dimer that is stabilized through hydrophobic interac-
tions mediated by a region adjacent to the HECT domain. 
HUWE1 counteracts its own inhibition through an intra-
molecular interaction with a segment located 50 residues 
upstream of the dimer-binding region. The HUWE1 inhibitor 
and tumor suppressor p14ARF have been shown to bind and 
disable this ‘activation segment’, thereby promoting inhibi-
tory dimerization. The involvement of the p14ARF inhibitor 
suggests that, in contrast to the previously discussed oli-
gomerization mechanisms, the inhibitory conformation of 
HUWE1 is not its default state. Structural analysis of the 
asymmetry of the HUWE1 dimer is intriguing, as it appears 
to affect the activity status of the two HECT domains. The 
HECT activity of one subunit in the dimer is impaired by 
a conformational lock of the C-lobe and blocked access to 
the catalytic site through interactions with the other subu-
nit. This latter subunit may be inhibited through allosteric 
interactions in the dimer; however, there is no indication 
that the flexibility of the C-lobe of this subunit is restricted, 
so its HECT domain may still be catalytically relevant (for 
details see [16, 119]). It appears that HUWE1 has a unique 
oligomerization mechanism in contrast to the previously dis-
cussed more common oligomerization mechanisms.
Post‑translational modifications of HECT E3 ligases
Various post-translational modifications of HECT E3 ligases 
are known to influence catalytic activity. Phosphorylation 
and ubiquitin-like modifications are types of post-transla-
tional modifications that commonly regulate various HECT 
E3s. Post-translational modifications can influence HECT 
activity by causing conformational changes in the E3 ligases 
or by influencing interactions of HECT E3s with adaptors or 
other regulatory proteins.
Phosphorylation
As previously discussed, phosphorylation of a PRR of ITCH 
can activate the HECT domain by relieving ITCH from its 
auto-inhibitory fold (see Fig. 7c). More specifically, ITCH 
is phosphorylated on three residues (S199, T222, S232) of 
a PPR residing in between the C2 and the first WW domain 
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by the JNK1 serine/threonine kinase [101, 120]. Recruit-
ment of JNK1 to ITCH is facilitated by an interaction of 
a D domain-like sequence within the N-lobe of the HECT 
domain. D domains consist of a group of basic residues fol-
lowed by a cluster of hydrophobic residues and have been 
shown to recruit MAP kinases [121]. Phosphorylation of 
the PRR region weakens the interaction between the WW 
domain region and the HECT domain, thereby disrupting 
the auto-inhibitory conformation of ITCH [101]. The PRR 
of ITCH is the only known phosphorylation site of JNK1 
in HECT E3s so this mechanism may be unique to ITCH.
NEDD4.1 is another example where the auto-inhibition 
of a HECT E3 is relieved by phosphorylation (Fig. 7d). The 
mechanism varies from the previously discussed type of 
NEDD4 family phosphorylation in that NEDD4.1 is phos-
phorylated at tyrosine residues in the C2 (Y43) and HECT 
domain (Y585), and this phosphorylation is catalyzed by 
the c-Src kinase [13]. The phosphorylated C2 and HECT 
domains of NEDD4.1 do not form the auto-inhibitory con-
formation most probably due to electrostatic repulsions 
caused by the phosphate groups. SYK-mediated tyrosine 
phosphorylation of HUWE1 is another example of how 
phosphorylation can disrupt auto-inhibition [122]. Unlike 
the previously discussed mechanism where addition of a 
phosphate moiety disrupts auto-inhibition, phosphorylation 
of HUWE1 causes the disassociation of HUWE1 from its 
inhibitor p14ARF. As discussed previously, the release of 
p14ARF enables HUWE1 to form an intramolecular con-
formation that counteracts the inhibitory dimer.
One of the earliest cases reported of a HECT E3 regulated 
by phosphorylation is that of NEDD4.2 [123]. NEDD4.2 is 
phosphorylated by the kinase SGK1 (serum/glucocorticoid-
regulated kinase 1) which utilizes a PY motif that binds to 
the E3s WW domains [124]. Serine phosphorylation (S468) 
of NEDD4.2 promotes recruitment of the adaptor protein 
14-3-3 to the phosphorylated NEDD4.2, thereby reducing 
the interaction of NEDD4.2 with its natural substrate ENaC 
(Epithelial  Na+ Channel), leading to increased ENaC surface 
expression.
Phosphorylation has also been shown to negatively regu-
late the E3 ligase activity of E6AP [117]. E6AP is tyrosine 
phosphorylated by c-Abl at residue 636 within its HECT 
domain. Mutation analysis of Y636 suggests that this residue 
controls the E3 ligase activity in a substrate-specific manner. 
This substrate specificity was shown for the E6AP phos-
phorylation resistant mutant Y636F, which has impaired 
E3 ligase activity towards the substrate hHR23A (human 
homolog of Rad23), although the ubiquitination of p53 in 
the presence of HPV E6 protein remained similar to that 
of wild-type E6AP. Analysis of the E6AP crystallographic 
trimer suggested that the Y636 is present in the second subu-
nit interface important for stabilization of E6AP oligom-
ers. Since the oligomerization of E6AP has been shown to 
promote its E3 ligase activity, it is conceivable that Y636 
phosphorylation regulates E6AP by deterring its ability to 
oligomerize. However, direct evidence for this is lacking.
Mutants of E6AP that influence its phosphorylation are 
not exclusive to those introduced with gene editing. A muta-
tion of threonine 485 to alanine in E6AP was identified in a 
whole-exome sequencing study aimed at identifying de novo 
mutations linked to autism [125]. Detailed analysis of the 
T485A mutation led to the discovery that T485 is phospho-
rylated by PKA (protein kinase A) as a mechanism to regu-
late E6AP E3 ligase activity [126]. The substitution of threo-
nine for an alanine makes it impossible to phosphorylate 
the residue and thereby disables phosphorylation control of 
E6AP. In HEK293T cells, it was shown that the  E6APT485A 
mutant actively auto-ubiquitinates, whereas a T485E mutant 
that mimics phosphorylated E6AP was inhibited for auto-
ubiquitination. In addition to reducing auto-ubiquitination, 
phosphorylated E6AP was also shown to have repressed E3 
ligase activity towards substrates such as hHR23A using 
in vitro analysis with the same mutants. Interestingly, the 
phosphorylation at T485 not only affects E3 ligase activity 
but also the ability of E6AP to self-associate. While wild-
type E6AP and the phospho-mimetic T485E mutant showed 
no self-association, the T485A mutant was able to interact 
with itself [126]. Whether the observed self-association of 
the T485A mutant is related to the crystallographic E6AP 
trimer remains to be elucidated. A recent follow-up study on 
the  E6APT485A mutant revealed that its expression results in 
increased Wnt (wingless-type MMTV integration site fam-
ily member) signaling through the ubiquitination of several 
proteasome subunits that are part of a distinct proteasome 
subdomain [127]. The ubiquitination of proteasome subu-
nits by E6AP reduces proteasome subunit abundance and 
activity [128, 129], resulting in the accumulation of stable 
β-catenin in the nucleus and subsequent activation of the 
Wnt signaling pathway [127]. Together, the studies on the 
phospho-resistant  E6APT485A show how the phosphorylation 
of one residue in a HECT E3 can control crucial cellular 
processes.
Ubiquitination/deubiquitination
Ubiquitination is another PTM that can regulate HECT E3 
ligases. HECT E3 ligases may be ubiquitinated by other E3 
ligases or ubiquitinate themselves in a process called auto-
ubiquitination. Often the ubiquitination of HECT E3 ligases 
functions as a mechanism of down-regulation by marking 
them for proteasomal degradation [130]. The regulatory 
effects of ubiquitin on HECT E3s are often controlled at the 
level of deubiquitination.
One HECT E3 that is negatively regulated by ubiquitina-
tion is TRIP12. TRIP12 is ubiquitinated and thereby targeted 
for proteasomal degradation. The control of this regulatory 
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degradation has been attributed to the DUB (deubiquitinat-
ing enzyme) USP7 [131]. USP7 associates with TRIP12 
and stabilizes it by deubiquitinating the HECT E3. This 
USP7–TRIP12 interaction has been shown to lead to the 
ubiquitination of the tumor suppressor  p14ARF. Unsurpris-
ingly, overexpression of USP7 and TRIP12 has been found 
to be associated with poor prognosis in cancers with aber-
rant expression of  p14ARF, such as hepatocellular carcinoma 
(HCC) [131]. Interestingly, USP7 itself is also targeted by 
TRIP12 for proteasomal degradation, indicating that they 
are mutual substrates for each other [132]. Thus, USP7 
increases the stability of TRIP12, whereas the TRIP12 does 
the opposite for USP7. Their effectiveness in targeting their 
cognate substrates relies on the homeostatic balance of the 
two proteins.
E6AP is another example of a HECT E3 ligase that is 
regulated by ubiquitination, serving as a substrate for UBR5, 
another HECT E3 ligase [133]. UBR5 negatively regulates 
E6AP abundance, and as a result the loss of UBR5 leads 
to higher levels and a longer half-life of E6AP. While this 
regulatory effect does occur in uninfected cells, most of the 
regulatory effects of UBR5 on E6AP are associated with 
HPV-infected cells. UBR5 interacts strongly with the HPV 
protein E6 and UBR5 impairs the ability of the E6/E6AP 
complex to target its substrates for degradation.
Ubiquitination by the yeast HECT E3 ligase, Rsp5 is 
negatively regulated through an interaction with the Ubp2 
deubiquitinating enzyme [134]. When in complex with the 
HECT E3 ligase, Ubp2 antagonizes the ubiquitination by 
Rsp5 by catalyzing the opposing reaction. In this case, the 
ubiquitin-associated (UBA) domain-containing protein Rup1 
mediates the coupling of Ubp2 to Rsp5. The UBA domain 
of Rup1 is not necessary for the interaction between Rsp5 
and Ubp2; however, the UBA domain does stimulate Ubp2 
deubiquitinating activity. The coupling of Rsp5 to the DUB 
is not necessarily a general negative regulator of Rsp5 ubiq-
uitination as it may have specificity towards the substrates it 
deubiquitinates. This substrate specificity would allow Ubp2 
to determine which Rsp5 substrates are ultimately ubiqui-
tinated. In addition, Ubp2 may play an important role in 
determining the topology of ubiquitin chains catalyzed by 
Rsp5. Deubiquitination can limit the extension of ubiquitin 
chains, thereby favoring mono-ubiquitination over poly-
ubiquitination of certain substrates.
SUMOylation
A recent study showed that the conjugation of the small 
ubiquitin-like modifier (SUMO) to SMURF2 regulates the 
activity of the SMURF2 HECT domain [15]. The SUMOyla-
tion of SMURF2 enhances its ubiquitination activity towards 
its target TβR1 (transforming growth factor B receptor 1), 
resulting in degradation and concomitant suppression of 
the TGF-β pathway. SUMOylation of SMURF2 is facili-
tated by the SUMO-E2-conjugating enzyme UBC9 and 
the SUMO E3 ligase PIAS3, which target distinct lysine 
residues of SMURF2. In a follow-up study, it was shown 
that SMURF2 SUMOylation suppresses the invasiveness 
of breast cancer organoids [135]. The mechanism through 
which SUMOylation regulates SMURF2 activity has not yet 
been determined. However, the location of the lysine resi-
dues SUMOylated by PIAS3, in the C2 domain (Lys26) and 
next to the C-terminal WW domain (Lys369), may suggest 
which regulatory mechanisms of the HECT E3 are altered. 
Proximity of the Lys369 SUMOylation site to the WW 
domains may affect the binding of these domains to the PY 
motifs of adaptor proteins, while SUMOylation of Lys26 
may be involved in the formation or disruption of the auto-
inhibitory conformations mediated by interactions between 
the C2 and HECT domain.
NEDD8 modification
Neddylation, the covalent binding of NEDD8 onto a target 
protein, is another ubiquitin-like modification that has been 
shown to regulate HECT E3 ligases. NEDD8 is 58% iden-
tical to ubiquitin and is covalently bound to its substrates 
in a process analogous to ubiquitination, using dedicated 
E1 (NAE) and E2s (Ube2M and Ube2F) for activation and 
transfer [136, 137]. Neddylation is a post-translational modi-
fication primarily known for regulating cullin-RING ligases 
(CRLs), a superfamily of RING E3 ligases [138]. The cullin 
subunit of the CRL complex needs to be neddylated on a 
single conserved lysine residue close to its RING-binding 
site to allow recruitment of the E2 critical for ubiquitin liga-
tion activity [139]. Various non-CRL neddylation targets 
have been proposed and are being investigated including 
the HECT E3 SMURF1 [14, 140]. SMURF1 catalyzes its 
own covalent attachment of NEDD8 to activate its ubiquitin 
ligase activity [14]. In contrast to the specific neddylation of 
a single lysine residue seen in CRL neddylation, SMURF1 
neddylates multiple lysine residues in various domains. 
Whether neddylation activates SMURF1 through promot-
ing E2–E3 interactions similar to CRL activation or through 
other mechanisms remains to be discovered. In addition to 
SMURF1, SMURF2 has also been shown to be neddylated 
and this neddylation leads to SMURF2 ubiquitination and 
its sequential degradation [141]. Non-covalent binding of 
NEDD8 has also been shown to promote ubiquitin ligase 
activity of SMURF1 and SMURF2 [142]. The Smurf pro-
teins contain a conserved domain that binds NEDD8, and 
disruption of this binding inhibits ubiquitin ligase activity 
of the Smurf HECT E3s [142]. A study of the other mem-
bers of the NEDD4 subfamily found that ITCH, NEDL1, 
and NEDL2 can also catalyze auto-neddylation in addition 
to the Smurf E3s [143]. Exceptionally, ITCH is the only 
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HECT that is neddylated on a single lysine residue, similar 
to the CRL E3s. ITCH also functions as a neddylation E3 
for JunB, targeting it for sequential ubiquitination and deg-
radation [143].
ISG15
The interferon inducible ISG15 is another ubiquitin-like 
protein that has been shown to regulate the activity of 
NEDD4.1. As discussed above, binding of free ISG15 
to NEDD4.1 blocks the interaction of the E3 with its E2 
thereby inhibiting the ubiquitin ligase (Fig. 6b) [97]. Nota-
bly, ISG15 expression is induced in response to viral infec-
tions and its inhibiting effect on NEDD4.1 is an effective 
counter mechanism to the virus. Similar to the NEDD8 
interaction with SMURF1 and SMURF2, ISG15 binds 
NEDD4.1 through non-covalent interactions. It is possible 
that NEDD4.1 is covalently modified by ISG15 (ISGyla-
tion); however, the interaction with free ISG15 seems to 
be sufficient to inhibit the E3s ubiquitination activity [98]. 
Whether post-translational modifications with ISG15 also 
regulate HECT E3 ligases remains to be determined. ISGyla-
tion has been shown to regulate non-HECT E3 ligases such 
as Parkin [144]. The ISGylation of Parkin is catalyzed by 
the HECT HERC6, which ISGylates two lysine residues 
of Parkin resulting in the disruption of its auto-inhibitory 
conformation.
Modulating HECT E3 activity
In addition to the variety of substrates HECT E3s can target 
specifically, there is also variety in the type of ubiquitin and 
ubiquitin-like moieties conjugated. HECT E3substrates may 
be mono-ubiquitinated or poly-ubiquitinated with additional 
variation in the lysine linkages in the poly-ubiquitin chains. 
HECT E3s have been shown to catalyze various poly-ubiqui-
tin chains such as Lys48-linked Ub chains, Lys63-linked Ub 
chains, or other linkage types [21, 22, 145, 146]. The result-
ing poly-ubiquitin chains can have different configurations 
ranging from linear to branched chains that each can consist 
of homotypic or mixed linkages. In addition to ubiquitin, 
ubiquitin-like modifiers such as NEDD8 and ISG15 can also 
be catalyzed by HECT E3 ligases. UBL modifiers can even 
be part of ubiquitin polymers [147], further emphasizing the 
wide variety of moieties that can possibly be conjugated by 
HECT E3s. Depending on the type of moiety, the substrate 
can be committed to divergent fates or display altered func-
tions. Importantly, various mechanisms exist that can regu-
late HECT E3 ligases to determine what type of ubiquitin 
and UBL mono- or polymers they catalyze.
An important determinant in the ubiquitin chain forma-
tion is the processivity of the E3 ligase. To efficiently form 
polyubiquitin chains, some HECT E3s have a processivity 
site (also called the “exosite”) in the N-lobe that binds the 
last ubiquitin of the growing chain to keep it in position 
for catalysis of the next ubiquitin. The processivity site 
interacts non-covalently with ubiquitin utilizing a series of 
predominantly hydrophobic residues to contact an interac-
tion surface on ubiquitin that involves the canonical Ile44 
hydrophobic patch [112, 148, 149]. Experiments using small 
molecule inhibitors have demonstrated that the processiv-
ity of NEDD4.1 can be regulated by targeting the exosite 
[150]. These small molecule inhibitors specifically bind to 
the processivity site, thereby disrupting the formation of 
polyubiquitin chains. Consequentially, NEDD4.1 changes to 
a distributive E3 ligase resulting in an increased amount of 
substrates that are mono-ubiquitinated. Whether the modula-
tion of NEDD4.1 by targeting its site of processivity is also 
utilized as a regulatory mechanism in the cell remains to be 
determined. Interestingly, however, a recent screen for ubiq-
uitin variants (UbVs) with increased affinity for the exosite 
has provided useful insights as to how HECT domain activ-
ity can be regulated and modulated [30]. Detailed biochemi-
cal analysis and HECT-UbV co-crystallization experiments 
revealed that UbV binding at the N-lobe exosite could modu-
late E3 ligase activity through a variety of mechanisms. For 
example, binding of the UbV to the NEDD4.2 and Rsp5 
exosite promoted the transfer of ubiquitin from E2 to E3, 
whereas other UbV interactions promoted ubiquitin transfer 
from E3 to the substrate. Another two UbVs were shown to 
modulate NEDD4.2 activity by decreasing processivity and 
increasing distributive multi-mono-ubiquitination. As the 
engineered UbVs are highly specific for one HECT E3 [30] 
by way of their design and selection process, their specificity 
may be useful to target and modulate a specific HECT E3 
ligase without affecting other HECT E3s in the cell.
To create certain ubiquitin polymers, HECT E3 ligases 
may also cooperate with other E3 ligases. For example, it 
was shown that a yeast HECT E3 Ufd4 can team up with 
the RING domain E3 ligase Ubr1 to poly-ubiquitinate its 
substrates [151]. The addition of the Ubr1 E3 to the UFD 
complex resulted in increased processivity towards the Ufd4 
substrates. Even though the preference to catalyze differ-
ent linkage polyubiquitin chains has not been observed in 
this Ubr1–Ufd4 interaction the cooperation of different 
E3 ligases may be a good explanation of such ubiquitin 
polymers.
Phosphorylated ubiquitin has recently been shown to 
modulate HECT E3 ligase to alter the specific lysine link-
age of the polyubiquitin chains it catalyzes. The HECT E3 
UBE3C normally forms ubiquitin chains with a mixture 
of both Lys29 and Lys48 linkages [22]; however, when it 
uses ubiquitin phosphorylated at serine 20 it preferably 
poly-ubiquitinates its substrates with Lys48-linked chains 
[152]. Phosphorylation of ubiquitin on S20 is found, among 
 J. Sluimer, B. Distel 
1 3
other PTMs, in mammalian cells [153]; however, the physi-
ological significance of S20 phospho-ubiquitin is currently 
unknown. The physiological importance of other phospho-
ubiquitins such as S65-phosphorylated ubiquitin has been 
demonstrated. Specifically, the generation of S65 phospho-
ubiquitins by PINK1 (PTEN-induced putative kinase 1) 
was shown to activate the RING-E3 parkin [154]. Thus, it is 
conceivable that S20-phospho-ubiquitins are also utilized in 
the cell as a mechanism to regulate E3s and perhaps PTMs 
of ubiquitin are more commonly involved in the regulation 
of HECT E3 ligases.
Summary and significance
A wide variety of mechanisms regulates the substrate speci-
ficity and control catalytic activity of the HECT E3 ligases. 
The domains N-terminal to the HECT domain play a pivotal 
role in determining substrate specificity, as they are impor-
tant interfaces that bind to adaptor proteins. Competitive 
inhibitors or post-translational modifications often control 
the interactions between adaptors and N-terminal domains, 
thereby modulating HECT E3 ligase activity.
The intermediate step of transferring ubiquitin from 
the E2 to the active site of the HECT increases the control 
exerted by the E3 ligase regarding subsequent catalysis. This 
contrasts to ubiquitination by RING E3s, where due to the 
direct transfer of ubiquitin from E2 to the substrate control 
of the reaction is largely determined by the E2-conjugat-
ing enzyme, especially with regards to the linkage type of 
ubiquitin chain formation. Consequently, mechanisms that 
control specificity and activity of HECT E3 ligases are of 
increased importance in determining the fate of HECT E3 
substrates. E2-conjugating enzymes remain important reg-
ulators of the HECT E3 ligases they cooperate with. The 
example of the SMURF2–UbcH7 interaction illustrated 
that the binding affinity of E2 to HECT E3 is an important 
factor in determining the catalytic activity and processivity 
of HECT E3s. Blocking of the E2–E3 interaction has also 
been shown to regulate HECT E3s as seen in the example of 
ISG15 binding to the E2-binding site of NEDD4.1.
A recurring type of mechanism that controls HECT 
E3 ligases, especially that of the NEDD4 subfamily, is 
the self-control of inter- and intramolecular interactions. 
Through interactions of the HECT domain with N-ter-
minal C2 or WW domains, NEDD4 family members can 
take up auto-inhibitory folds or form homodimers that 
block catalytic activity until an external regulator unlocks 
the HECT E3. Mechanisms that can relieve these auto-
inhibitory and oligomeric forms such as post-translational 
modifications, allosteric protein–protein interactions, and 
 Ca2+ interactions have been highlighted for the NEDD4 
family in this review. The trimers formed by Rsp5 and 
E6AP were shown to have opposing regulatory outcomes. 
Oligomerization using a similar trimerization interface 
appears to lead to inhibition of Rsp5 and activation of 
E6AP. To understand how HECT domain-mediated trim-
erization can lead to these opposing outcomes in activity, 
it will be key to determine the structural and functional 
contributions of the region N-terminal to HECT domain.
HECT E3s are capable of catalyzing a variety of ubiq-
uitin polymers and can additionally catalyze the attach-
ment of the ubiquitin-like modifiers such as ISG15 and 
NEDD8. The processivity of HECT E3 ligases may also 
be an important factor in determining the outcome for its 
substrates. Various studies discussed in this review pre-
sented regulatory mechanisms that influenced HECT E3 
ligase processivity. The lysine linkage of ubiquitin chains 
is often determined primarily by the HECT E3; however, 
regulators can modulate HECT E3s to alter the lysine link-
age they catalyze. Thus, substrates of HECT E3s can be 
post-translationally modified with a wide variety of ubiq-
uitin polymers that may have various functional outcomes. 
For a full understanding of the functional consequences 
of HECT E3substrate ubiquitination, we need to not only 
identify these substrates, but also characterize the inter-
ubiquitin connectivity of their ubiquitin polymers. While 
challenging, such an approach has become feasible due 
to the recent advances in targeted proteomics techniques 
[155].
Regulation of HECT E3 ligases plays an important part 
in the determination of cell fates and as such disruption of 
HECT E3 function is often implicated in disease. Under-
standing the mechanisms that regulate HECT E3s will be 
critical in the search for treatments that intervene with or 
enhance HECT E3 functions. Various diseases have been 
associated with HECT E3 function. For example, increased 
E6AP activity has been associated with autism and most 
cervical cancers [56, 126], whereas reduced activity of 
E6AP has been implicated in Angelman syndrome [9, 10]. 
Regulating HECT E3s by targeting their upstream regulators 
may be a promising strategy. For example, a study showed 
that stimulating PKA by using pharmacological agents was 
an effective method to turn down E6AP activity in neurons 
[126]. While most strategies using pharmacological agents 
may focus on inhibition, in some cases activation or modula-
tion of the HECT E3 might be a more appropriate strategy. 
The screen using ubiquitin variants (UbV) found various 
sites on the HECT domain that upon interaction with an 
UbV resulted in activation or modulation of the HECT E3. 
Perhaps pharmacological agents can be developed that tar-
get the same activation or modulation sites as a therapeutic 
strategy. The wide variety of regulatory mechanisms that 
control HECT E3s in the cell should serve as an indicator 
of the many possible avenues that can be taken in order to 
manipulate the activity of HECT E3 ligases.
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